Adeno-Associated Virus (AAV) is an easily adaptable and versatile viral vector technology that can be explored and engineered for several applications in gene therapy. rAAV has been reported to be safe and effective in clinical and pre-clinical settings and thus can fuel the much- required improvisations in the field of gene therapy. reagent kit provides the essential tools required to produce desired rAAV particles.
This kit is composed of three main parts (a) AAV RepCap plasmid (b) AAV Helper plasmid (c) AAV expression plasmid suitable to clone the Gene of Interest (GOI). The kit also includes a positive control expressing YFP as GOI. The three plasmids encode the elements necessary to prepare recombinant AAV particles by transfection into HEK293 cells, which harbor the necessary adenovirus genes to produce the AAV particles.
ENZENE offers custom designed research grade plasmids suitable for any gene of interest, AAV packaging / triple transfections for Gene therapy applications and use in in vitro transcription (IVT).
This reagent kit (AAV serotype 2 helper free packaging plasmids) includes AAV2 Rep/Cap plasmid (pENZ345a), AAV helper plasmid (pENZ345d), AAV expression plasmid (pENZ345e) suitable to clone the gene of interest (GOI), and a positive control expressing the YFP as GOI. Please click here for more details on AAVENZENE 2.
This reagent kit (AAV serotype 5 helper free packaging plasmids) includes AAV5 Rep/Cap plasmid (pENZ345b), AAV helper plasmid (pENZ345d), AAV expression plasmid (pENZ345e) suitable to clone the gene of interest (GOI), and a positive control expressing the YFP as GOI. Please click here for more details on AAVENZENE 5.
This reagent Pack (AAV serotype 6 helper free packaging plasmids) includes AAV6 Rep/Cap plasmid (pENZ345c), AAV helper plasmid (pENZ345d), AAV expression plasmid (pENZ345e) suitable to clone the gene of interest (GOI), and a positive control expressing the YFP as GOI. Please click here for more details on AAVENZENE 6.
Your trusted partners for manufacturing research and GMP grade plasmids!
Biologics are an innovative treatment option for a wide range of maladies such as Rheumatoid Arthritis, Cancer, Crohn’s disease as well as other chronic or life-threatening ailments. The capital involved in developing a biologic molecule is exorbitant and exceeds that of any chemical drugs. As a result, these fall beyond the reach of many.
With the introduction of BPCI act of 2009 which paved the way for Biosimilars, an Alternate to Expensive Biologic Medicine was born.
A biosimilar is a copy of a biological medicine that is similar, but not identical, to the original medicine. The path to their approval is shorter as the number of clinical trials and spend on research & development is much less than on the original biologics, thus fostering cheaper costs.
Biosimilars are for Every Patient
Enzene has one of the strongest pipelines in Biosimilars with many molecules in early as well as late stage of development. Enzene’s core team has extensive experience in developing and launching biosimilars in EU, USA,APAC, MENA and LATAM.
Molecule (Originator) | Marketed indications | Development | Pre-Clinical | Clinical | Launch | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Molecule | Marketed indications | ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|